GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (STU:SU6) » Definitions » Cyclically Adjusted Price-to-FCF

Surmodics (STU:SU6) Cyclically Adjusted Price-to-FCF : 61.59 (As of Jun. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Surmodics Cyclically Adjusted Price-to-FCF?

As of today (2024-06-25), Surmodics's current share price is €38.80. Surmodics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €0.63. Surmodics's Cyclically Adjusted Price-to-FCF for today is 61.59.

The historical rank and industry rank for Surmodics's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

STU:SU6' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 15.32   Med: 37.43   Max: 77.77
Current: 60.08

During the past years, Surmodics's highest Cyclically Adjusted Price-to-FCF was 77.77. The lowest was 15.32. And the median was 37.43.

STU:SU6's Cyclically Adjusted Price-to-FCF is ranked worse than
69.49% of 236 companies
in the Medical Devices & Instruments industry
Industry Median: 42.03 vs STU:SU6: 60.08

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Surmodics's adjusted free cash flow per share data for the three months ended in Mar. 2024 was €0.399. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €0.63 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Surmodics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Surmodics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Cyclically Adjusted Price-to-FCF Chart

Surmodics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.34 38.34 55.26 36.98 42.15

Surmodics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.78 39.14 42.15 55.75 42.02

Competitive Comparison of Surmodics's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Surmodics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surmodics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Surmodics's Cyclically Adjusted Price-to-FCF falls into.



Surmodics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Surmodics's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=38.80/0.63
=61.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surmodics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Surmodics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.399/131.7762*131.7762
=0.399

Current CPI (Mar. 2024) = 131.7762.

Surmodics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.316 100.560 0.414
201409 0.272 100.428 0.357
201412 0.329 99.070 0.438
201503 0.082 99.621 0.108
201506 0.336 100.684 0.440
201509 0.102 100.392 0.134
201512 0.410 99.792 0.541
201603 0.184 100.470 0.241
201606 0.342 101.688 0.443
201609 0.220 101.861 0.285
201612 0.029 101.863 0.038
201703 0.069 102.862 0.088
201706 0.092 103.349 0.117
201709 0.305 104.136 0.386
201712 -0.044 104.011 -0.056
201803 1.451 105.290 1.816
201806 -0.363 106.317 -0.450
201809 0.139 106.507 0.172
201812 -0.475 105.998 -0.591
201903 0.027 107.251 0.033
201906 -0.101 108.070 -0.123
201909 0.652 108.329 0.793
201912 -0.169 108.420 -0.205
202003 0.100 108.902 0.121
202006 0.716 108.767 0.867
202009 0.017 109.815 0.020
202012 -0.396 109.897 -0.475
202103 0.923 111.754 1.088
202106 0.111 114.631 0.128
202109 -0.091 115.734 -0.104
202112 -0.498 117.630 -0.558
202203 -0.349 121.301 -0.379
202206 -0.296 125.017 -0.312
202209 -0.223 125.227 -0.235
202212 -0.795 125.222 -0.837
202303 -0.436 127.348 -0.451
202306 1.667 128.729 1.706
202309 0.033 129.860 0.033
202312 -0.618 129.419 -0.629
202403 0.399 131.776 0.399

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Surmodics  (STU:SU6) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Surmodics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Surmodics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Surmodics (STU:SU6) Business Description

Traded in Other Exchanges
Address
9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

Surmodics (STU:SU6) Headlines

No Headlines